A pragmatic single-blind randomised controlled trial and health economic evaluation of leukotriene receptor antagonists in primary care at steps two and three of the national asthma guidelines

Conditions

Asthma Respiratory Asthma

Price D, Musgrave SD, Shepstone L, Hillyer EV, Sims EJ, Gilbert RF, Juniper EF, Ayres JG, Kemp L, Blyth A, Wilson EC, Wolfe S, Freeman D, Mugford HM, Murdoch J, Harvey I.

2011-05-01171 citations

10.1056/nejmoa1010846

Cost effectiveness of leukotriene receptor antagonists versus long-acting beta-2 agonists as add-on therapy to inhaled corticosteroids for asthma: a pragmatic trial.

Wilson EC, Price D, Musgrave SD, Sims EJ, Shepstone L, Murdoch J, Mugford HM, Blyth A, Juniper EF, Ayres JG, Wolfe S, Freeman D, Gilbert RF, Hillyer EV, Harvey I.

2010-01-0113 citations

10.2165/11537560-000000000-00000

Cost effectiveness of leukotriene receptor antagonists versus inhaled corticosteroids for initial asthma controller therapy: a pragmatic trial.

Wilson EC, Sims EJ, Musgrave SD, Shepstone L, Blyth A, Murdoch J, Mugford HM, Juniper EF, Ayres JG, Wolfe S, Freeman D, Gilbert RF, Harvey I, Hillyer EV, Price D.

2010-01-017 citations

10.2165/11537550-000000000-00000

Interventions

LTRAs versus alternative treatment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Not provided at time of registration.

Exclusion criteria

Exclusion criteria: Not provided at time of registration.

Design outcomes

Primary

Measure	Time frame
1. Need for further treatment intervention 2. Frequency of exacerbations 3. Short-acting beta agonist use 4. Hospitalisations 5. Time off work 6. Daily inhaled steroid dose (step three) 7. Asthma symptoms 8. Morning and diurnal variation in peak flow 9. Those with eczema/rhinitis comparative change in disease assessment	—

Secondary

Measure	Time frame
Not provided at time of registration.	—

Countries

United Kingdom

Outcome results

None listed